Innovent Biologics Inc (IVBXF:OTCMKTS)
$9.95 0.00 (0.00%)
Analysed Innovent Biologics Inc (IVBXF:OTCMKTS) News Sources
Pfizer secures China nod for obesity drug as generics loom
Bloomberg on MSN
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Yahoo Finance
China approves Pfizer GLP-1 drug for weight management
AOL
China clears weight-loss shot as Pfizer enters crowded market
Benzinga on MSN
Top pharma companies racing to launch a weight-loss pill
Reuters
China approves Pfizer drug for weight loss
Hiru News
Pharmalittle: We’re reading about an FDA-UniQure tussle, a Pfizer obesity drug approval in China, and more
STAT
GLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026
Yahoo Finance
InnoCare's next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
Le Lézard
Top biotech deals in February 2026
Labiotech.eu
What is the current price of Innovent Biologics Inc (IVBXF:OTCMKTS)?
The current price of Innovent Biologics Inc (IVBXF:OTCMKTS) is $9.95.
Innovent Biologics Inc (IVBXF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of Innovent Biologics Inc (IVBXF:OTCMKTS) since the previous trading day is $0.00.
Innovent Biologics Inc (IVBXF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of Innovent Biologics Inc (IVBXF:OTCMKTS) since the previous trading day is 0.00%.
What is This Week's average sentiment score for Innovent Biologics Inc (IVBXF:OTCMKTS)?
This Week's average sentiment score for Innovent Biologics Inc (IVBXF:OTCMKTS) is 76 out of 100.
What is This Week's average sentiment for Innovent Biologics Inc (IVBXF:OTCMKTS)?
This Week's sentiment for Innovent Biologics Inc (IVBXF:OTCMKTS) is .
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.